The US Onychomycosis Market (2017 Edition)
Scope of the Report
The report entitled “The US Onychomycosis Market (2017 Edition)”, provides analysis of the US onychomycosis market, with detailed analysis of market size and growth, market share and economic impact of the industry. The analysis includes the market by value, by volume and by segments. The report also includes the detailed analysis of the segments of the onychomycosis market, comprising of market by value, by volume and by average prices.
Valeant Pharmaceuticals, Pfizer, Inc., Novartis AG and Johnson & Johnson are some of the key players operating in the US onychomycosis market, whose company profiling has been done in the report. In this segment of the report, business overview, financial overview and business strategies of the companies are provided.
Company Coverage
Onychomycosis is a condition of fungal nail infection. Onychomycosis begins in the nail bed and progresses to the nail plate, causing the nail to become discolored, deformed, and even separated from the nail bed. Onychomycosis has a significant chance of reoccurrence. Of all the nail abnormalities in the world, around 50% are the case of onychomycosis. In most of the cases it occurs in the toenails. Onychomycosis is not a life threatening disease but, may persist or worsen if not treated. Symptoms of onychomycosis are changes in appearance of the nail, interference with standing, walking, and exercising, pain, discomfort, etc. The causative pathogens of onychomycosis include dermatophytes (most common), Candida, and nondermatophytic molds.
There are five types of Onychomycosis: Distal Subungual Onychomycosis, White superficial onychomycosis, Proximal subungual onychomycosis, Endonyx onychomycosis and Candidal onychomycosis. Two types of treatments are available of onychomycosis: Oral Treatment and Topical Treatment. Oral treatment includes: Terbinafine, Itraconazole, etc. and topical treatment includes Kerydin, Jublia, etc. Nonpharmacologic approaches are also there, which includes the following: Laser treatment, Photodynamic therapy, etc.
The US onychomycosis market (prescription drugs) has increased with a healthy growth rate over the years and is expected to increase further during the forecasted period. The US onychomycosis market is supported by various growth drivers, such as rising per capita healthcare expenditure, increasing diabetic patients, ageing population, introduction of new drugs, etc. Yet, the market faces certain challenges, such as, reimbursements, low awareness, side effects, etc.
The report entitled “The US Onychomycosis Market (2017 Edition)”, provides analysis of the US onychomycosis market, with detailed analysis of market size and growth, market share and economic impact of the industry. The analysis includes the market by value, by volume and by segments. The report also includes the detailed analysis of the segments of the onychomycosis market, comprising of market by value, by volume and by average prices.
Valeant Pharmaceuticals, Pfizer, Inc., Novartis AG and Johnson & Johnson are some of the key players operating in the US onychomycosis market, whose company profiling has been done in the report. In this segment of the report, business overview, financial overview and business strategies of the companies are provided.
Company Coverage
- Valeant Pahrmaceuticals
- Pfizer, Inc.
- Johnson and Johnson
- Novartis AG
Onychomycosis is a condition of fungal nail infection. Onychomycosis begins in the nail bed and progresses to the nail plate, causing the nail to become discolored, deformed, and even separated from the nail bed. Onychomycosis has a significant chance of reoccurrence. Of all the nail abnormalities in the world, around 50% are the case of onychomycosis. In most of the cases it occurs in the toenails. Onychomycosis is not a life threatening disease but, may persist or worsen if not treated. Symptoms of onychomycosis are changes in appearance of the nail, interference with standing, walking, and exercising, pain, discomfort, etc. The causative pathogens of onychomycosis include dermatophytes (most common), Candida, and nondermatophytic molds.
There are five types of Onychomycosis: Distal Subungual Onychomycosis, White superficial onychomycosis, Proximal subungual onychomycosis, Endonyx onychomycosis and Candidal onychomycosis. Two types of treatments are available of onychomycosis: Oral Treatment and Topical Treatment. Oral treatment includes: Terbinafine, Itraconazole, etc. and topical treatment includes Kerydin, Jublia, etc. Nonpharmacologic approaches are also there, which includes the following: Laser treatment, Photodynamic therapy, etc.
The US onychomycosis market (prescription drugs) has increased with a healthy growth rate over the years and is expected to increase further during the forecasted period. The US onychomycosis market is supported by various growth drivers, such as rising per capita healthcare expenditure, increasing diabetic patients, ageing population, introduction of new drugs, etc. Yet, the market faces certain challenges, such as, reimbursements, low awareness, side effects, etc.
1. EXECUTIVE SUMMARY
2. INTRODUCTION
2.1 Onychomycosis: An Overview
2.1.1 Signs and Symptoms
2.1.2 Causes of Onychomycosis
2.2 Types of Onychomycosis
2.3 Treatment for Onychomycosis
3. THE US MARKET ANALYSIS
3.1 The US Onychomycosis Market by Prevalence
3.1.1 The US Onychomycosis Market by Prevalence
3.1.2 The US Onychomycosis Market Prevalence by Segments
3.2 The US Nail Care Market: An Analysis
3.2.1 The US Nail Care Market by Value
3.2.2 The US Nail Care Market by Segments
3.3 The US Kerydin Drug Market: An Anlalysis
3.3.1 The US Kerydin Drug Market by Value
3.3.2 The US Kerydin Drug Market by Volume
3.4 The US Jublia Drug Market: An Analysis
3.4.1 The US Jublia Drug Market by Value
3.4.2 The US Jublia Drug Market by Volume
3.5 The US Generic Drugs Market: An Analysis
3.5.1 The US Generic Drugs Market by Value
3.6 Onychomycosis Market: New Drugs Overview
3.6.1 Global Skin Infection Market- Phase III Drugs (Onychomycosis) Pipeline Forecast
3.6.2 MOB-015
3.6.3 VT-1161
4. COMPETITIVE LANDSCAPE
4.1 Competition in Onychomycosis Prescription Market: An Overview
4.2 Financial Comparison of Major Players of the US Onychomycosis Market
5. COMPANY PROFILING
5.1 Valeant Pharmaceuticals
5.1.1 Business Overview
5.1.2 Financial Overview
5.1.3 Business Strategy
5.2 Pfizer
5.2.1 Business Overview
5.2.2 Financial Overview
5.2.3 Business Strategy
5.3 Johnson & Johnson
5.3.1 Business Overview
5.3.2 Financial Overview
5.3.3 Business Strategy
5.4 Novartis AG
5.4.1 Business Overview
5.4.2 Financial Overview
5.4.3 Business Strategy
2. INTRODUCTION
2.1 Onychomycosis: An Overview
2.1.1 Signs and Symptoms
2.1.2 Causes of Onychomycosis
2.2 Types of Onychomycosis
2.3 Treatment for Onychomycosis
3. THE US MARKET ANALYSIS
3.1 The US Onychomycosis Market by Prevalence
3.1.1 The US Onychomycosis Market by Prevalence
3.1.2 The US Onychomycosis Market Prevalence by Segments
3.2 The US Nail Care Market: An Analysis
3.2.1 The US Nail Care Market by Value
3.2.2 The US Nail Care Market by Segments
3.3 The US Kerydin Drug Market: An Anlalysis
3.3.1 The US Kerydin Drug Market by Value
3.3.2 The US Kerydin Drug Market by Volume
3.4 The US Jublia Drug Market: An Analysis
3.4.1 The US Jublia Drug Market by Value
3.4.2 The US Jublia Drug Market by Volume
3.5 The US Generic Drugs Market: An Analysis
3.5.1 The US Generic Drugs Market by Value
3.6 Onychomycosis Market: New Drugs Overview
3.6.1 Global Skin Infection Market- Phase III Drugs (Onychomycosis) Pipeline Forecast
3.6.2 MOB-015
3.6.3 VT-1161
4. COMPETITIVE LANDSCAPE
4.1 Competition in Onychomycosis Prescription Market: An Overview
4.2 Financial Comparison of Major Players of the US Onychomycosis Market
5. COMPANY PROFILING
5.1 Valeant Pharmaceuticals
5.1.1 Business Overview
5.1.2 Financial Overview
5.1.3 Business Strategy
5.2 Pfizer
5.2.1 Business Overview
5.2.2 Financial Overview
5.2.3 Business Strategy
5.3 Johnson & Johnson
5.3.1 Business Overview
5.3.2 Financial Overview
5.3.3 Business Strategy
5.4 Novartis AG
5.4.1 Business Overview
5.4.2 Financial Overview
5.4.3 Business Strategy
LIST OF FIGURES
Figure 1: Types of Onychomycosis
Figure 2: Treatment for Onychomycosis
Figure 3: US Onychomycosis Market by Prevalence; 2016 (Million)
Figure 4: The US Onychomycosis Market Prevalence by Segments; 2016
Figure 5: The US Nail Care Market by Value; Jun16-Apr17 (US$ Million)
Figure 6: The US Nail Care Market by Segments; Q2016
Figure 7: The US Kerydin Drug Market by Value; 2Q2015-1Q2016 (US$ Million)
Figure 8: The US Kerydin Drug Market by Volume; 4Q2014-1Q2016 (Count)
Figure 9: The US Jublia Drug Market by Value; 4Q2014-1Q2016 (US$ Million)
Figure 10: The US Jublia Drug Market by Volume; 4Q2014-1Q2016 (Count)
Figure 11: The US Generic Drugs Market by Value; 2012-2017 (US$ Million)
Figure 12: Phase III Drugs (Onychomycosis) Pipeline Forecast; 2018-2026 (US$ Million)
Figure 13: Valeant Revenue; 2012-2016 (US$ Billion)
Figure 14: Valeant Revenue by Segments; 2016 (Percentage, %)
Figure 15: Pfizer Revenue; 2012-2016 (US$ Billion)
Figure 16: Pfizer Revenue by Segments; 2016 (Percentage, %)
Figure 17: Johnson & Johnson Total Sales; 2012-2016 (US$ Billion)
Figure 18: Johnson & Johnson Sales by Segments; 2016 (Percentage, %)
Figure 19: Novartis AG Business Segments
Figure 20: Novartis AG Total Sales; 2012-2016 (US$ Billion)
Figure 21: Novartis AG Sales by Segments; 2016 (Percentage, %)
Table 1: Treatments Available for Onychomycosis
Table 2: Financial Comparison of Major Players of the US Onychomycosis Market
Figure 1: Types of Onychomycosis
Figure 2: Treatment for Onychomycosis
Figure 3: US Onychomycosis Market by Prevalence; 2016 (Million)
Figure 4: The US Onychomycosis Market Prevalence by Segments; 2016
Figure 5: The US Nail Care Market by Value; Jun16-Apr17 (US$ Million)
Figure 6: The US Nail Care Market by Segments; Q2016
Figure 7: The US Kerydin Drug Market by Value; 2Q2015-1Q2016 (US$ Million)
Figure 8: The US Kerydin Drug Market by Volume; 4Q2014-1Q2016 (Count)
Figure 9: The US Jublia Drug Market by Value; 4Q2014-1Q2016 (US$ Million)
Figure 10: The US Jublia Drug Market by Volume; 4Q2014-1Q2016 (Count)
Figure 11: The US Generic Drugs Market by Value; 2012-2017 (US$ Million)
Figure 12: Phase III Drugs (Onychomycosis) Pipeline Forecast; 2018-2026 (US$ Million)
Figure 13: Valeant Revenue; 2012-2016 (US$ Billion)
Figure 14: Valeant Revenue by Segments; 2016 (Percentage, %)
Figure 15: Pfizer Revenue; 2012-2016 (US$ Billion)
Figure 16: Pfizer Revenue by Segments; 2016 (Percentage, %)
Figure 17: Johnson & Johnson Total Sales; 2012-2016 (US$ Billion)
Figure 18: Johnson & Johnson Sales by Segments; 2016 (Percentage, %)
Figure 19: Novartis AG Business Segments
Figure 20: Novartis AG Total Sales; 2012-2016 (US$ Billion)
Figure 21: Novartis AG Sales by Segments; 2016 (Percentage, %)
Table 1: Treatments Available for Onychomycosis
Table 2: Financial Comparison of Major Players of the US Onychomycosis Market
